AntagomiR-106b-5p increases proliferation and migration of PASMCs. (A) After treatment with PDGF or antagomiR-106b-5p, the viability of PASMCs was assessed using a Cell Counting Kit-8 assay. (B) PCNA protein expression following the various treatments. (C) Transwell invasion assays were performed to assess invasion following the various treatments. Scale bars: 20 μm. *P<0.05 vs. Ctrl group. #P<0.05 vs. PDGF group. miR, microRNA; PDGF, platelet-derived growth factor; PASMC, pulmonary artery smooth muscle cell; PCNA, proliferating cell nuclear antigen; NC, negative control; Ctrl, control.